In a regulatory filing, Mirum Pharmaceuticals (MIRM) disclosed that its director Patrick Heron bought 131.4K shares of common stock on January 23rd in a total transaction size of $9.0M. Shares are up 2.5% afterhours at $101.73.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals Completes Bluejay Acquisition, Expands Liver Portfolio
- Mirum Pharmaceuticals price target raised to $130 from $102 at H.C. Wainwright
- Mirum Pharmaceuticals price target raised to $101 from $94 at Evercore ISI
- Mirum Pharmaceuticals price target raised to $95 from $81 at Baird
- Mirum Pharmaceuticals price target raised to $102 from $81 at H.C. Wainwright